Immunomedics (IMMU -0.3%) announces
that Trodelvy (sacituzumab govitecan-hziy) is now available through
major specialty distributors in the U.S. and that the first patient was
treated on April 29, 2020.
Trodelvy is the first anti-Trop-2 ADC recently
approved by the FDA for the treatment of adult patients with metastatic
triple-negative breast cancer who have received at least two prior
therapies for metastatic disease.
https://seekingalpha.com/news/3568278-immunomedics-trodelvy-now-available-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.